Emilie Gerard

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Severe oral lichenoid reactions associated with immune checkpoint inhibitors.

Severe oral lichenoid reactions associated with immune checkpoint inhibitors.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 30, 2026

Prognostic classification of skin adnexal carcinomas: Results from a prospective study of 980 patients in the French CARADERM network.

Prognostic classification of skin adnexal carcinomas: Results from a prospective study of 980 patients in the French CARADERM network.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 22, 2026

Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study.

Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study.

Journal: The oncologist

Published: October 15, 2025

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 22, 2025

Dupilumab for immune checkpoint inhibitors-induced pruritic dermatoses: A retrospective, multicentric study.

Dupilumab for immune checkpoint inhibitors-induced pruritic dermatoses: A retrospective, multicentric study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 01, 2025

Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.

Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.

Journal: Melanoma research

Published: March 25, 2025

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.

Journal: RMD open

Published: February 14, 2025

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Journal: The British journal of dermatology

Published: December 10, 2024

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 15, 2024

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.

Journal: Joint bone spine

Published: March 20, 2024

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.

Journal: Frontiers in oncology

Published: March 19, 2024

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).

Journal: The oncologist

Published: December 17, 2023

Showing 1-12 of 50

Last Updated: 09/26/2026